Computational and Structural Biotechnology Journal (Jan 2021)

A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis

  • Pooja Gupta,
  • Sherine E. Thomas,
  • Shaymaa A. Zaidan,
  • Maria A. Pasillas,
  • James Cory-Wright,
  • Víctor Sebastián-Pérez,
  • Ailidh Burgess,
  • Emma Cattermole,
  • Clio Meghir,
  • Chris Abell,
  • Anthony G. Coyne,
  • William R. Jacobs, Jr.,
  • Tom L. Blundell,
  • Sangeeta Tiwari,
  • Vítor Mendes

Journal volume & issue
Vol. 19
pp. 3491 – 3506

Abstract

Read online

The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion of L-glutamate to L-arginine. Arginine auxotrophs (argB/argF deletion mutants) of Mycobacterium tuberculosis are rapidly sterilised in mice, while inhibition of ArgJ with Pranlukast was found to clear chronic M. tuberculosis infection in a mouse model. Enzymes in the arginine biosynthetic pathway have therefore emerged as promising targets for anti-tuberculosis drug discovery. In this work, the ligandability of four enzymes of the pathway ArgB, ArgC, ArgD and ArgF is assessed using a fragment-based approach. We identify several hits against these enzymes validated with biochemical and biophysical assays, as well as X-ray crystallographic data, which in the case of ArgB were further confirmed to have on-target activity against M. tuberculosis. These results demonstrate the potential for more enzymes in this pathway to be targeted with dedicated drug discovery programmes.

Keywords